In a speech emphasizing the importance of compromise, likely presidential candidate Hillary Clinton said that there may be room for that dirty word in Washington when it comes to repealing the 2.3% medical device tax. That is a key demand of Republicans, not to mention of the device industry.
Boston Scientific won a positive recommendation from an FDA panel for its stroke-fighting Watchman device, even as panel members expressed doubt that the product would work well in patients who are eligible for traditional drug therapy.
Startup CoheroHealth, developer of the AsthmaHero app and spirometer for measuring the volume of air inhaled and exhaled by the lungs, will test its solution on 50 patients at New York City's Mount Sinai Medical Center.
Implantable tissue repair player Histogenics has filed for an initial public offering to raise up to $65 million. The financing is to fund an ongoing Phase III trial for its NeoCart, an implant to repair knee cartilage damage. Meanwhile, Molecular diagnostics company AutoGenomics is hoping the third time's the charm with its IPO filing for up to $60 million.
Academics hope to enhance a new mouse model created to better understand how pain is transmitted in the body. Ada Poon, an assistant professor of electrical engineering at Stanford University, is working as part of a team to build a wireless device that incorporates existing optogenetics research.
The European Union suspended shipments of EndoBarrier, an obesity device from GI Dynamics, for reasons undisclosed by the company. GI Dynamics said the situation is temporary and does not apply to product already in the hands of hospitals and distributors.
Becton Dickinson plans to finance its acquisition of CareFusion with a $9.1 billion bridge loan, joining the ranks of other med tech outfits which have recently turned to loans for pending M&A deals.
FDA Commissioner Margaret Hamburg devoted a large part of her luncheon remarks at the annual AdvaMed MedTech Conference in Chicago to boosting the American device industry's global competitiveness.
The federal Open Payments database launched by the U.S.Health and Human Services Dept. announced that the medical device industry paid doctors at least $200 million last year. The database is taking the heat, however, for being generally inaccurate, incomplete and difficult to navigate
The long slog toward approval for Boston Scientific's Watchman implant continues today when it goes before a FDA advisory panel for a third time.
A recent report by Evaluate MedTech released at the annual AdvaMed med tech conference in Chicago found that M&A deal value in the med tech sector grew by 363% year over year in the first half of 2014 to $30 billion.
A pilot program to remotely monitor blood pressure and weight for congestive heart failure patients is being expanded. The program shows how patients and healthcare providers can work together via technology to reduce hospital readmission.
History and science have joined forces. Canadian researchers have discovered and identified a heart and gut disease caused by a genetic mutation that can be traced back to the 12th century Vikings.
NanoString Technologies is teaming up with Brigham and Women's Hospital to study genomic biomarkers and develop diagnostic tests for cancer, furthering the company's plans for accelerated growth.
Unilife, the injectable technology provider, has inked a deal with Sanofi to be the French drugmaker's sole provider of cartridge-based wearable injectors for the next 15 years.
GE has appointed John Flannery as the president and CEO of GE Healthcare. He was previously the SVP of business development at the company. The move comes after the healthcare division shrank a bit during the first half.
Medical retinal imaging player Optos, the U.K. National Health Service and academics will participate in a £10 million ($16 million) collaboration to enable earlier detection of eye diseases that threaten vision.
Scientists have discovered a blood biomarker useful in identifying patients at risk for developing diabetes.
Wearble health monitors might soon become a thing of the past--replaced by science fiction-sounding "invisibles." Futuristic implantable microchips are shaping up to be the cutting-edge way to monitor health. The idea is to make digital health monitoring a little less all-consuming.
Amid growing competition in the neuromodulation field, California devicemaker Nevro filed plans for an initial public offering valued at up to $115 million to ramp up development of its innovative pain-management implant.